Back to CELG-RI
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
0 competitors in Relapsed or Refractory T-cell Lymphomas
View Full LandscapeDrug Information
Target Indication
Relapsed or Refractory T-cell Lymphomas
Clinical Trial
NCT06035497Last updated: 2/19/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts